TY - JOUR
T1 - Serum-based protein biomarkers of bladder cancer
T2 - A pre- and post-operative evaluation
AU - Bansal, Navneeta
AU - Gupta, Ashok Kumar
AU - Gupta, Ashish
AU - Sankhwar, Satya Narain
AU - Mahdi, Abbas Ali
N1 - Publisher Copyright:
© 2016 Elsevier B.V..
PY - 2016/5/30
Y1 - 2016/5/30
N2 - Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes.
AB - Urinary bladder cancer (BC) is the fifth most common cancer worldwide with alarming mortality. Shortcomings of urine cytology and cystoscopy and sparse improvements in the survival rate prompt us to evolve surrogate serum based protein biomarkers to identify BC at an early stage. Previously, we showed that aberrant expression of S100A4, S100A8, S100A9, carbonic anhydrase I (CA I) and Annexin V proteins in pre-operative BC serum compared to healthy controls (HC) (Clin Chim Acta, 2014; 36: 97-103). Here we further evaluate and validate these findings with follow-up post-operative BC patients. This study was conducted on 160 sera samples comprising healthy controls (HC, n = 52), pre-operative (n = 55) and post-operative (n = 53) BC patients. Enzyme-linked immunosorbent assay (ELISA) was used to appraise the aberrantly expressed proteins. ELISA results revealed that the expression levels of S100A8, S100A9, S100A4, and CA I were gradually and significantly reduced; concomitantly, Annexin V was progressively and significantly increased in post-operative compared to pre-operative BC sera samples. Serum protein biomarkers appear to be an encouraging and least-invasive approach for BC identification and prognosticating patient outcomes.
KW - Enzyme-linked immunosorbent assay
KW - Serum proteomics
KW - Urinary bladder cancer
UR - http://www.scopus.com/inward/record.url?scp=84959105824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959105824&partnerID=8YFLogxK
U2 - 10.1016/j.jpba.2016.02.026
DO - 10.1016/j.jpba.2016.02.026
M3 - Article
C2 - 26922578
AN - SCOPUS:84959105824
SN - 0731-7085
VL - 124
SP - 22
EP - 25
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
ER -